Year: 2021

news_6

BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

Third approval for BRUKINSA in China and second approval in WM worldwide CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ:...

news_6

Global Warming Policies in China, 2020 Report – China Begins to Move Toward the Realization of Reducing CO2 Emissions by 2030 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Warming Policies in China" report has been added to ResearchAndMarkets.com's offering. On September 22nd, China announced that...